HSC01
clear graphic clear graphic
clear graphic

The Social Determinants of Health: Relevance to Cancer Disparities

Posted: Wednesday, January 19, 2011

Share |

clear graphicclear graphic
clear graphicclear graphic
clear graphicEmail Printer Friendly Format
 

Contact: Elizabeth Allen, (210) 450-2020

SALSI-funded speaker series focuses on cancer health disparities

Who:
Dr. Paula Braveman, professor of family and community medicine, director of the Center on Social Disparities in Health, University of California, San Francisco

What:
Social determinants are the social and environmental factors within a community that affect a person’s health. These are important to understand, as a person can be part of overlapping communities, according to Dr. Braveman’s research.

When:
Jan. 27, 2011, 4 p.m. Refreshments will be served

Where:
Cancer Therapy & Research Center, 7979 Wurzbach Road, fourth floor, Grossman Building, Mabee Conference Room

The lecture is the second in a series sponsored by the San Antonio Life Sciences Institute (SALSI). SALSI is a collaboration between The University of Texas Health Science Center at San Antonio and the University of Texas at San Antonio for projects and programs to enhance research, teaching and service. The Institute for Health Promotion Research (IHPR) at the Health Science Center is coordinating the series. Both the CTRC and the IHPR are in the Health Science Center School of Medicine. For more information on the series, visit http://ihpr.uthscsa.edu/salsi_lectures.html.


###


The University of Texas Health Science Center at San Antonio, one of the country’s leading health sciences universities, ranks in the top 3 percent of all institutions worldwide receiving National Institutes of Health (NIH) funding. Research and other sponsored program activity totaled a record $259 million in fiscal year 2009. The university’s schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have produced approximately 26,000 graduates. The $744 million operating budget supports eight campuses in San Antonio, Laredo, Harlingen and Edinburg. For more information on the many ways “We make lives better®,” visit www.uthscsa.edu.


The University of Texas at San Antonio is one of the fastest growing higher education institutions in Texas and one of nine academic universities and six health institutions in the UT System. As a multicultural institution, UTSA aims to be a national research university providing access to educational excellence and preparing citizen leaders for the global environment.

UTSA serves more than 30,300 students in 65 bachelor’s, 49 master’s and 21 doctoral degree programs in the colleges of Architecture, Business, Education and Human Development, Engineering, Honors, Liberal and Fine Arts, Public Policy, Sciences and Graduate School. Founded in 1969, UTSA is an intellectual and creative resource center and a socioeconomic development catalyst for Texas and beyond. More information online at www.utsa.edu/today.


The Institute for Health Promotion Research (IHPR) investigates the causes and solutions to the unequal impact of cancer and chronic disease among Latinos in San Antonio, South Texas and the nation. The IHPR, founded in 2006, is based at The University of Texas Health Science Center at San Antonio with a satellite office in Harlingen, Texas. The IHPR uses evidence-guided research, training and community outreach to improve the health of those at a disadvantage due to race/ethnicity or social determinants. Visit the IHPR online at http://ihpr.uthscsa.edu or read our blog.

The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the elite academic cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only four in Texas. A leader in developing new drugs to treat cancer, the CTRC Institute for Drug Development (IDD) conducts one of the largest oncology Phase I clinical drug programs in the world, and participates in development of cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit www.ctrc.net.

 
bottom bar

»printer friendly format...
»view more articles by issue#...
»search articles by keywords...
Arrow - to top
Arrow - to top